399 related articles for article (PubMed ID: 31932840)
1. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM
Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840
[TBL] [Abstract][Full Text] [Related]
2. Use of Eculizumab in Pediatric Patients with High-Risk Transplantation-Associated Thrombotic Microangiopathy: Outcomes and Risk Factors Associated with Response and Survival. A Retrospective Study on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
Benítez Carabante MI; Bueno D; Alonso García L; López Torija I; Marsal J; Fernandez Navarro JM; Uria Oficialdegui ML; Panesso M; Molina B; Beléndez Bieler C; Palomo P; Pérez Martínez A; Diaz-de-Heredia C
Transplant Cell Ther; 2024 Jun; 30(6):601.e1-601.e13. PubMed ID: 38521410
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
Schoettler M; Lehmann L; Li A; Ma C; Duncan C
Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
[TBL] [Abstract][Full Text] [Related]
4. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
[TBL] [Abstract][Full Text] [Related]
5. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
[TBL] [Abstract][Full Text] [Related]
6. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
[TBL] [Abstract][Full Text] [Related]
7. Eculizumab and thrombotic microangiopathy after hematopoietic stem cell transplantation: A report on its efficacy and safety in two pediatric patients.
Genere L; Bacchetta J; Bertrand Y; Javouhey E; Cheikh N; Sellier-Leclerc AL
Arch Pediatr; 2018 Nov; 25(8):485-488. PubMed ID: 30340942
[TBL] [Abstract][Full Text] [Related]
8. Eculizumab treatment in paediatric patients diagnosed with aHUS after haematopoietic stem cell transplantation: a HSCT-TMA case series from Japanese aHUS post-marketing surveillance.
Ito S; Saito A; Sakurai A; Watanabe K; Karakawa S; Miyamura T; Yokosuka T; Ueki H; Goto H; Yagasaki H; Kinoshita M; Ozeki M; Yokoyama N; Teranishi H
Bone Marrow Transplant; 2024 Mar; 59(3):315-324. PubMed ID: 38102212
[TBL] [Abstract][Full Text] [Related]
9. Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children.
Schoettler ML; Patel S; Bryson E; Deeb L; Watkins B; Qayed M; Chandrakasan S; Fitch T; Silvis K; Jones J; Chonat S; Williams KM
Transplant Cell Ther; 2024 Mar; 30(3):336.e1-336.e8. PubMed ID: 38145741
[TBL] [Abstract][Full Text] [Related]
10. Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients.
Rudoni J; Jan A; Hosing C; Aung F; Yeh J
Eur J Haematol; 2018 Sep; 101(3):389-398. PubMed ID: 29920784
[TBL] [Abstract][Full Text] [Related]
11. Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC.
de Fontbrune FS; Galambrun C; Sirvent A; Huynh A; Faguer S; Nguyen S; Bay JO; Neven B; Moussi J; Simon L; Xhaard A; Resche-Riggon M; O'Meara A; Fremeaux-Bacchi V; Veyradier A; Socié G; Coppo P; de Latour RP
Transplantation; 2015 Sep; 99(9):1953-9. PubMed ID: 25651309
[TBL] [Abstract][Full Text] [Related]
12. Interferon-complement loop in transplant-associated thrombotic microangiopathy.
Jodele S; Medvedovic M; Luebbering N; Chen J; Dandoy CE; Laskin BL; Davies SM
Blood Adv; 2020 Mar; 4(6):1166-1177. PubMed ID: 32208488
[TBL] [Abstract][Full Text] [Related]
13. Early Increase in Complement Terminal Pathway Activation Marker sC5b-9 Is Predictive for the Development of Thrombotic Microangiopathy after Stem Cell Transplantation.
Horváth O; Kállay K; Csuka D; Mező B; Sinkovits G; Kassa C; Stréhn A; Csordás K; Sinkó J; Prohászka Z; Kriván G
Biol Blood Marrow Transplant; 2018 May; 24(5):989-996. PubMed ID: 29339271
[TBL] [Abstract][Full Text] [Related]
14. A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation-associated TMA.
Jodele S; Dandoy CE; Aguayo-Hiraldo P; Lane A; Teusink-Cross A; Sabulski A; Mizuno K; Laskin BL; Freedman J; Davies SM
Blood; 2024 Mar; 143(12):1112-1123. PubMed ID: 37946262
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
Menne J; Delmas Y; Fakhouri F; Licht C; Lommelé Å; Minetti EE; Provôt F; Rondeau E; Sheerin NS; Wang J; Weekers LE; Greenbaum LA
BMC Nephrol; 2019 Apr; 20(1):125. PubMed ID: 30971227
[TBL] [Abstract][Full Text] [Related]
16. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
[TBL] [Abstract][Full Text] [Related]
18. A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.
Jodele S; Laskin BL; Dandoy CE; Myers KC; El-Bietar J; Davies SM; Goebel J; Dixon BP
Blood Rev; 2015 May; 29(3):191-204. PubMed ID: 25483393
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cell transplantation-associated thrombotic microangiopathy accompanied by renal arteriolar C4d deposition.
Sakamoto K; Imamura T; Osone S; Nishimura A; Nishida M; Ishida H; Hosoi H
Pediatr Transplant; 2015 Jun; 19(4):E97-100. PubMed ID: 25735190
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults.
Jodele S; Davies SM; Lane A; Khoury J; Dandoy C; Goebel J; Myers K; Grimley M; Bleesing J; El-Bietar J; Wallace G; Chima RS; Paff Z; Laskin BL
Blood; 2014 Jul; 124(4):645-53. PubMed ID: 24876561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]